Masitinib is a c-KIT/PDGFR inhibitor currently under clinical investigation as a potential target of cell-signaling pathways associated with neurodegeneration, including neuroinflammation, excitotoxicity, and cognitive improvement in AD (Dubreuil et al., 2009; Folch et al., 2015; Fagiani et al., 2020; Dubois et al., 2023). Here, PDGFRB is linked to Alzheimer disease.